Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.800
-0.110 (-5.76%)
Feb 21, 2025, 4:00 PM EST - Market closed
Akebia Therapeutics Revenue
Akebia Therapeutics had revenue of $37.43M in the quarter ending September 30, 2024, a decrease of -10.98%. This brings the company's revenue in the last twelve months to $169.88M, down -12.53% year-over-year. In the year 2023, Akebia Therapeutics had annual revenue of $194.62M, down -33.46%.
Revenue (ttm)
$169.88M
Revenue Growth
-12.53%
P/S Ratio
2.16
Revenue / Employee
$1,017,240
Employees
167
Market Cap
392.73M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 194.62M | -97.86M | -33.46% |
Dec 31, 2022 | 292.48M | 80.83M | 38.19% |
Dec 31, 2021 | 211.65M | -82.99M | -28.17% |
Dec 31, 2020 | 294.64M | -40.36M | -12.05% |
Dec 31, 2019 | 335.00M | 127.26M | 61.26% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AKBA News
- 12 days ago - Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline - Seeking Alpha
- 17 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Akebia Therapeutics Announces Multiple Positive Business Updates - PRNewsWire
- 7 weeks ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 2 months ago - Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - PRNewsWire
- 3 months ago - Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - PRNewsWire
- 3 months ago - Q3 2024 Earnings: Hold Akebia Therapeutics - Seeking Alpha